Bronchiolitis in children: The Saudi initiative of bronchiolitis diagnosis, management, and prevention (SIBRO)

Adel S Alharbi, Mansour Alqwaiee, Mohammed Y Al-Hindi, Rafat Mosalli, Abdullah Al-Shamrani, Saleh Alharbi, Abdullah Yousef, Amal Al Aidaroos, Turki Alahmadi, Aisha Alshammary, Abeer Miqdad, Yazan Said, Abdulrahman AlnemriAnnals of Thoracic Medicine 2018 13(3):127-143 Bronchiolitis is the leading cause of admissions in children less than two years of age. It has been recognized as highly debated for many decades. Despite the abundance of literature and the well-recognized importance of palivizumab in the high risk groups, and despite the existence of numerous, high-quality, recent guidelines on bronchiolitis, the number of admissions continues to increase. Only supportive therapy and few therapeutic interventions are evidence based and proved to be effective. Since Respiratory Syncytial Virus (RSV) is the major cause of bronchiolitis, we will focus on this virus mostly in high risk groups like the premature babies and children with chronic lung disease and cardiac abnormalities. Further, the prevention of RSV with palivizumab in the high risk groups is effective and well known since 1998; we will discuss the updated criteria for allocating infants to this treatment, as this medication is expensive and should be utilized in the best condition. Usually, diagnosis of bronchiolitis is not challenging, however there has been historically no universally accepted and validated scoring system to assess the severity of the condition. Severe RSV, especially in high risk children, is un...
Source: Annals of Thoracic Medicine - Category: Respiratory Medicine Authors: Source Type: research